Announcement • Apr 17
Enveric Biosciences, Inc. announced that it expects to receive $5.000002 million in funding Enveric Biosciences, Inc. announced a private placement to issue 2,222,223 shares at a price of $2.25 per share for gross proceeds of $5,000,001.75 on April 16, 2026. The company will also issue options at an exercise price of $2.00 per share, and Series I warrants will expire five years after the effective date of the resale registration statement and the short-term Series J warrants will expire eighteen months after the effective date of the resale registration statement. The company raises funding pursuant to exemption provided under regulation D. The closing of the offering is expected to occur on or about April 17, 2026, subject to the satisfaction of customary closing conditions. Announcement • Apr 15
Enveric Biosciences, Inc., Annual General Meeting, May 28, 2026 Enveric Biosciences, Inc., Annual General Meeting, May 28, 2026. Announcement • Feb 20
Enveric Biosciences Reports Eb-003 Bret Receptor Engagement Assay Data Enveric Biosciences announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and b-arrestin-mediated signaling downstream of the 5-HT2A receptor. Multiple independent, peer-reviewed studies have previously shown that selective activation of 5-HT2A receptor, by either Gq-biased or b-arrestin-biased agonists, can independently produce antidepressant- and anxiolytic-like effects in preclinical models, suggesting that therapeutic benefit can arise from activation of either pathway. The new data was generated using proprietary bioluminescence resonance energy transfer (BRET) assays. Enveric developed and validated in-house BRET assays to characterize EB-003's intracellular signaling profile because commercial assays capable of reliably measuring pathway-specific 5-HT2A signaling were not available. The data demonstrate biologically relevant engagement of both Gq and b-arrestin pathways. Enveric's new data also indicate that EB-003 exhibits a modest preference toward b-arrestin over Gq signaling relative to serotonin, the native ligand of the receptor. Ongoing research is exploring the mechanistic significance of this apparent bias. Importantly, both pathways appear to be engaged at levels consistent with biological relevance. A recently published study in Nature employing BRET assays and complementary techniques provides additional mechanistic clarity regarding signaling downstream of 5-HT2A. The study reports that Gi signaling downstream of 5-HT 2A was required for hallucinogenic effects in the experimental models evaluated, while Gq signaling mediated antidepressant- and anxiety-like benefits in preclinical systems. These findings indicate that therapeutic benefit and hallucinations may arise from distinct intracellular pathways. Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity withouthallucinogenic effects. Enveric's lead candidate, EB-003., is the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience. For more information, Enveric developed and validated In-house BRET assays, Enveric developed and validate in-house BRET assay to characterize EB-003's intrusion of 5-HT2A signaling profile because commercial assays able to reliably measuring pathway-specific 5 -HT2A signaling were not availability. The data demonstrated biologically relevant engagement of both GQ and b-arrestin pathway. Enveric's new Data also indicate that EB-003 exhibit a modest preference toward b-ARrestin over Gq signaling compared to serotonin, the native lig and of the receptor. Ongoing Research is exploring the mechanistic significance. A recently published study in nature employing BRET assays and complement techniques provides additional mechanistic clarity about signaling downstream of 5-HT1A. The study reports that Guq signaling downstream of 5- HT2A was required for hallucin carcinogenic effects in the experimental models evaluate, while Gq signaling downstream of 5-HS2A.1 The study reports that Gi signaling upstream of 5-HT2A was required for pharmacokinetics, including of the Gi pathway, to further characterize its unique signaling mechanisms. EB-003 is being developed to be a non-hallucinogenic neuroplastogen intended to support streamlined treatment therapies, including potential at-home administration. The Company continues to advance EB-003 through IND-enabling studies. 
